Loading...
Loading...
IOBT| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.2M |
| Gross Profit | -0.2M |
| Operating Expense | 23.5M |
| Operating I/L | -23.5M |
| Other Income/Expense | -0.3M |
| Interest Income | 1.7M |
| Pretax | -22.1M |
| Income Tax Expense | -0.4M |
| Net Income/Loss | -21.7M |
IO Biotech, Inc. is a clinical-stage biopharmaceutical company specializing in immune-modulating cancer therapies. Their lead product candidate, IO102-IO103, targets immunosuppressive proteins such as IDO and PD-L1, and is in phase 2 clinical trial for melanoma and phase 1 trials for lung, head and neck, bladder, and melanoma cancer. Additionally, they are developing IO112, a product candidate designed to target T cells recognizing epitopes derived from Arginase 1 for cancer treatment.
